Claudio Melo de Gusmao

Claudio Melo de Gusmao

Auto-generated profile, based on publicly available information

Claudio Melo de Gusmao

Division of Child Neurology, Department of Neurology Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC‐FMUSP) Sao Paulo Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
Maya ChopraMaya Chopra
Maya Chopra
DGDustin L. Gable
Dustin L. Gable
JLJamie Love‐Nichols
Jamie Love‐Nichols
ATAlexa Tsao
Alexa Tsao
SRShira Rockowitz
Shira Rockowitz
SSSiddharth Srivastava
Siddharth Srivastava
Objectives: Cerebral palsy (CP) is the most common childhood motor disability, yet its link to single‐gene disorders is under‐characterized. To explore the genetic landscape of CP, we conducted whole exome sequencing (WES) in a cohort of patients with CP.Methods: We performed comprehensive phenotyping and WES on a prospective cohort of individuals with cryptogenic CP (who meet criteria for CP; have no risk factors), non‐cryptogenic CP (who meet criteria for CP; have at least one risk factor), and CP masqueraders (who could be diagnosed with CP, but have regression/progressive symptoms). We characterized motor phenotypes, ascertained medical comorbidities, and classified brain MRIs. We analyzed WES data using an institutional pipeline.Results: We included 50 probands in this analysis (20 females, 30 males). Twenty‐four had cryptogenic CP, 20 had non‐cryptogenic CP, five had CP masquerader classification, and one had unknown classification. Hypotonic‐ataxic subtype showed a difference in prevalence across the classification groups (p = 0.01). Twenty‐six percent of participants (13/50) had a pathogenic/likely pathogenic variant in 13 unique genes (ECHS1, SATB2, ZMYM2, ADAT3, COL4A1, THOC2, SLC16A2, SPAST, POLR2A, GNAO1, PDHX, ACADM, ATL1), including one patient with two genetic disorders (ACADM, PDHX) and two patients with a SPAST‐related disorder. The CP masquerader category had the highest diagnostic yield (n = 3/5, 60%), followed by the cryptogenic CP category (n = 7/24, 29%). Fifteen percent of patients with non‐cryptogenic CP (n = 3/20) had a Mendelian disorder on WES.Interpretation: WES demonstrated a significant prevalence of Mendelian disorders in individuals clinically diagnosed with CP, including in individuals with known CP risk factors.

5 April 2022 in Movement Disorders
Verified
Journal Article
Closed access
AMAurélie Méneret
Aurélie Méneret
SMShekeeb S. Mohammad
Shekeeb S. Mohammad
LCLaura Cif
Laura Cif
DDDiane Doummar
Diane Doummar
CDClaudio DeGusmao
Claudio DeGusmao
EREmmanuel Roze
Emmanuel Roze

1 August 2014 in Pediatric Neurology
Verified
Journal Article
Closed access
CGClaudio M. de Gusmão
Claudio M. de Gusmão
RGRejean M Guerriero
Rejean M Guerriero
MBMiya Elizabeth Bernson-Leung
Miya Elizabeth Bernson-Leung
DPDanielle Pier
Danielle Pier
PIPatricia I. Ibeziako
Patricia I. Ibeziako
JWJeff L. Waugh
Jeff L. Waugh

23 March 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
CGClaudio M. de Gusmão
Claudio M. de Gusmão
LGLucas Garcia
Lucas Garcia
MMMohamad A. Mikati
Mohamad A. Mikati
SSSamantha Su
Samantha Su
LSLaura Silveira-Moriyama
Laura Silveira-Moriyama
Paroxysmal movement disorders include paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, paroxysmal exercise-induced dyskinesia, and episodic ataxias. In recent years, there has been renewed interest and recognition of these disorders and their intersection with epilepsy, at the molecular and pathophysiological levels. In this review, we discuss how these distinct phenotypes were constructed from a historical perspective and discuss how they are currently coalescing into established genetic etiologies with extensive pleiotropy, emphasizing clinical phenotyping important for diagnosis and for interpreting results from genetic testing. We discuss insights on the pathophysiology of select disorders and describe shared mechanisms that overlap treatment principles in some of these disorders. In the near future, it is likely that a growing number of genes will be described associating movement disorders and epilepsy, in parallel with improved understanding of disease mechanisms leading to more effective treatments.

6 June 2023 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PMPoornima Jayadev Menon
Poornima Jayadev Menon
CNChristelle Nilles
Christelle Nilles
LSLaura Silveira‐Moriyama
Laura Silveira‐Moriyama
RYRuiyi Yuan
Ruiyi Yuan
CGClaudio M. de Gusmao
Claudio M. de Gusmao
TPTamara Pringsheim
Tamara Pringsheim
Background: Adenylyl cyclase 5 (ADCY5)‐related movement disorder (ADCY5‐RMD) is a rare, childhood‐onset disease resulting from pathogenic variants in theADCY5gene. The clinical features, diagnostic options, natural history, and treatments for this disease are poorly characterized and have never been established through a structured approach.Objective: This scoping review attempts to summarize all available clinical literature on ADCY5‐RMD.Methods: Eighty‐seven articles were selected for inclusion in this scoping review. The majority of articles identified were case reports or case series.Results: These articles demonstrate that patients with ADCY5‐RMD suffer from permanent and/ or paroxysmal hyperkinetic movements. The paroxysmal episodes can be worsened by environmental triggers, in particular the sleep–wake transition phase in the early morning. Occurrence of nocturnal paroxysmal dyskinesias and perioral twitches are highly suggestive of the diagnosis when present. In the majority of patients intellectual capacity is preserved. ADCY5‐RMD is considered a non‐progressive disorder, with inter‐individual variations in evolution with aging. Somatic mosaicism, mode of inheritance and the location of the mutation within the protein can influence phenotype.Conclusions: The current evidence for therapeutic options for ADCY5‐RMD is limited: caffeine, benzodiazepines and deep brain stimulation have been consistently reported to be useful in case reports and case series.

22 July 2016 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
CGClaudio M. de Gusmão
Claudio M. de Gusmão
TFTania Fuchs
Tania Fuchs
AMAndrew Moses
Andrew Moses
TMTrisha Multhaupt‐Buell
Trisha Multhaupt‐Buell
PSPhillip C. Song
Phillip C. Song
NSNutan Sharma
Nutan Sharma
Objective: Spasmodic dysphonia is a focal dystonia of the larynx with heterogeneous manifestations and association with familial risk factors. There are scarce data to allow precise understanding of etiology and pathophysiology. Screening for dystonia‐causing genetic mutations has the potential to allow accurate diagnosis, inform about genotype‐phenotype correlations, and allow a better understanding of mechanisms of disease.Study Design: Cross‐sectional study.Setting: Tertiary academic medical center.Subjects and Methods: We enrolled patients presenting with spasmodic dysphonia to the voice clinic of our academic medical center. Data included demographics, clinical features, family history, and treatments administered. The following genes with disease‐causing mutations previously associated with spasmodic dysphonia were screened: TOR1A (DYT1), TUBB4 (DYT4), and THAP1 (DYT6).Results: Eighty‐six patients were recruited, comprising 77% females and 23% males. A definite family history of neurologic disorder was present in 15% (13 of 86). Average age (± standard deviation) of symptom onset was 42.1 ± 15.7 years. Most (99%; 85 of 86) were treated with botulinum toxin, and 12% (11 of 86) received oral medications. Genetic screening was negative in all patients for the GAG deletion in TOR1A (DYT1) and in the 5 exons currently associated with disease‐causing mutations in TUBB4 (DYT4). Two patients tested positive for novel/rare variants in THAP1 (DYT6).Conclusion: Genetic screening targeted at currently known disease‐causing mutations in TOR1A, THAP1, and TUBB4 appears to have low diagnostic yield in sporadic spasmodic dysphonia. In our cohort, only 2 patients tested positive for novel/rare variants in THAP1. Clinicians should make use of genetic testing judiciously and in cost‐effective ways.